Lorenza Rimassa: New Survival Benchmark for People Living with Advanced Biliary Tract Cancer
Lorenza Rimassa, Head of Hepatopancreatobiliary Oncology at Humanitas Research Hospital and Head of External Relations at International Liver Cancer Association (ILCA), shared a post on X about a paper by Do-Youn Oh et al. published in the Journal of Hepatology:
“New survival benchmark for people living with advanced biliary tract cancer – findings in the Journal of Hepatology solidify durvalumab plus GemCis as the standard first-line treatment. EASL news via EurekAlert!”
Title: Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
Authors: Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Renata Zaucha, Antonio Avallone, Juan Cundom, Aleksandra Kuzko, Julie Wang, Ioannis Xynos, Arndt Vogel, Juan W. Valle.
You can read the Full Article in the Journal of Hepatology.
You can find more posts featuring Lorenza Rimassa in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023